Affiliation:
1. Terrence Donnelly Heart Center St. Michael's Hospital University of Toronto Ontario Canada
2. Division of Cardiology Duke University Medical Center Duke Clinical Research Institute Durham NC
3. Department of Medicine Emory University School of Medicine Atlanta GA
4. Chronic Disease Research Group Minneapolis Medical Research Foundation and Department of Medicine Hennepin County Medical Center University of Minnesota Minneapolis MN
Abstract
Background
We sought to determine temporal trends in use of evidence‐based therapies and clinical outcomes among myocardial infarction (
MI)
patients with chronic kidney disease (
CKD
).
Methods and Results
MI
patients from the NCDR (National Cardiovascular Data Registry) Chest Pain–
MI
Registry between January 2007 and December 2015 were categorized into 3 groups by degree of
CKD
(end‐stage renal disease on dialysis,
CKD
[glomerular filtration rate <60 mL/min per 1.73 m
2
] not requiring dialysis, and no
CKD
[glomerular filtration rate ≥60 mL/min per 1.73 m
2
]). Logistic regression modeling was used to determine the association between calendar years (2014–2015 versus 2007–2008) and each outcome by degree of
CKD
. Among 325 396 patients with ST‐segment–elevation MI, 1.0% had end‐stage renal disease requiring dialysis, and 26.1% had
CKD
not requiring dialysis. Use of primary percutaneous coronary intervention increased over time regardless of the presence or degree of
CKD
(
P=
0.40 for interaction). In‐hospital mortality was temporally higher among patients with preserved renal function (odds ratio: 1.25; 95% confidence interval, 1.13–1.39;
P
<0.001) but not among patients with
CKD
(
P
=0.035 for interaction). Among 506 876 non–ST‐segment–elevation MI patients, 3.4% had end‐stage renal disease requiring dialysis, and 34.4% had
CKD
not requiring dialysis. P2Y
12
inhibitor use within 24 hours increased over time only among dialysis patients (
P
for interaction <0.001). Use of coronary angiography and percutaneous coronary intervention also increased, with the greatest increase among dialysis patients (
P
for interaction <0.001 and <0.001, respectively). In‐hospital mortality was lower, regardless of the presence or degree of
CKD
(
P
=0.64 for interaction).
Conclusions
Uptake of evidence‐based medical and invasive therapies has increased over the past decade among
MI
patients with
CKD
, particularly dialysis patients, with improvement of in‐hospital mortality observed among patients with non–ST‐segment–elevation MI, but not ST‐segment–elevation MI, and
CKD
.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献